Predicting antimicrobial susceptibilities for Escherichia coli and Klebsiella pneumoniae isolates using whole genomic sequence data

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 10, 2013, Pages 2234-2244

  Stoesser, N ^a,b   Batty, E M ^c   Eyre, D W ^a   Morgan, M ^b   Wyllie, D H ^b   Del Ojo Elias, C ^a   Johnson, J R ^d   Walker, A S ^a   Peto, T E A ^a   Crook, D W ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antibiotic; Gram negative; Phenotype

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; CONTIG; GENTAMICIN; MEROPENEM;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIUM ISOLATE; BROTH DILUTION; DIFFUSION; ESCHERICHIA COLI; GENE; GENE SEQUENCE; GENOME; GENOTYPE; HUMAN; KLEBSIELLA PNEUMONIAE; MUTATION; PHENOTYPE; PLASMID; PREDICTION; RETROSPECTIVE STUDY;

ANTIBIOTIC; GRAM-NEGATIVE; PHENOTYPE;

ANTI-BACTERIAL AGENTS; BACTEREMIA; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; GENOME, BACTERIAL; GREAT BRITAIN; HUMANS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA;

EID: 84888796738     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt180     Document Type: Article

References (40)

1. Didelot X, Bowden R, Wilson DJ et al. Transforming clinical microbiology with bacterial genome sequencing. Nat Rev Genet 2012; 13: 601-12.
2. Jorgensen JH, Ferraro MJ. Antimicrobial susceptibility testing: a reviewof general principles and contemporary practices. Clin Infect Dis 2009; 49: 1749-55.
3. BSAC. BSAC Methods for Antimicrobial Susceptibility Testing; Version 11. http://bsac.org.uk/wp-content/uploads/2012/02/Version-11.1-2012-Final-.pdf (19 March 2013, date last accessed).
4. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-second Informational Supplement M100-S22. CLSI,Wayne, PA, USA, 2012.
5. Andrews JM. The development of the BSAC standardized method of disc diffusion testing. J Antimicrob Chemother 2001; 48 Suppl 1: 29-42.
6. Bulik CC, Fauntleroy KA, Jenkins SG et al. Comparison of meropenemMICs and susceptibilities for carbapenemase-producing Klebsiella pneumoniae isolates by various testing methods. J Clin Microbiol 2010; 48: 2402-6.
7. Snyder JW, Munier GK, Johnson CL. Direct comparison of the BD Phoenix systemwiththeMicroScanWalkAwaysystemfor identificationandantimicrobial susceptibility testingofEnterobacteriaceaeandnonfermentativegram-negative organisms. J ClinMicrobiol 2008; 46: 2327-33.
8. Zankari E, Hasman H, Kaas RS et al. Genotyping using whole-genome sequencing is a realistic alternative to surveillance based on phenotypic antimicrobial susceptibility testing. J Antimicrob Chemother 2013; 68: 771-7.
9. HPA, UK. Escherichia coli Bacteraemia in England, Wales and Northern Ireland, 2007-2011. http://www.hpa.org.uk/hpr/archives/2012/hpr2212_ ecoli_bctrm2011.pdf (15 January 2013, date last accessed).
10. HPA, UK. Klebsiella, Enterobacter, Serratia and Citrobacter spp. Bacteraemia, England, Wales and Northern Ireland: 2006-2010. http://www. hpa.org.uk/webc/HPAwebFile/HPAweb_C/1287142531496 (15 January 2013, date last accessed).
11. Gagliotti C, Balode A, Baquero F et al. Escherichia coliandStaphylococcus aureus: bad news and good news from the European antimicrobial resistance surveillance network (EARS-Net, formerly EARSS), 2002-2009. Euro Surveill 2011; 16: pii1/419819.
12. Schlackow I, Stoesser N, Walker AS et al. Increasing incidence of Escherichia coli bacteraemia is driven by an increase in antibioticresistant isolates: electronic database study in Oxfordshire 1999-2011. J Antimicrob Chemother 2012; 67: 1514-24.
13. Webster DP, Young BC, Morton R et al. Impact of a clonal outbreak of extended-spectrum b-lactamase-producing Klebsiella pneumoniae in the development and evolution of bloodstream infections by K. pneumoniae and Escherichia coli: an 11 year experience in Oxfordshire, UK. J Antimicrob Chemother 2011; 66: 2126-35.
14. Paterson DL. Resistance in gram-negative bacteria: Enterobacteriaceae. Am J Med 2006; 119 Suppl 1: S20-8.
15. EUCAST. Breakpoint Tables for Interpretation of MICs and Zone Diameters; Version 3.0 (1 January 2013). http://www.eucast.org/fileadmin/ src/media/PDFs/EUCAST_files/Disk_ test_documents/EUCAST_Breakpoint_table_v_3.0.pdf (11 February 2013, date last accessed).
16. BSAC. Use of Gradient Tests for Determination of MICs by BSAC Methodology. http://bsac.org.uk/wp-content/uploads/2012/02/Use-ofgradient-tests.pdf (27 December 2012, date last accessed).
17. Jacoby G, Bush K.b-Lactamase Classification and Amino Acid Sequences for TEM, SHV and OXA Extended-spectrum and Inhibitor-resistant Enzymes. http://www.lahey.org/Studies/ (27 December 2012, date last accessed).
18. Ramirez MS, Tolmasky ME. Aminoglycoside modifying enzymes. Drug Resist Updat 2010; 13: 151-71.
19. Lartigue MF, Leflon-Guibout V, Poirel L et al. Promoters P3, Pa/Pb, P4, and P5 upstream from blaTEM genes and their relationship to b-lactam resistance. Antimicrob Agents Chemother 2002; 46: 4035-7.
20. Mulvey MR, Bryce E, Boyd DA et al. Molecular characterization of cefoxitin-resistant Escherichia coli from Canadian hospitals. Antimicrob Agents Chemother 2005; 49: 358-65.
21. Caroff N, Espaze E, Bérard I et al. Mutations in the ampC promoter of Escherichia coli isolates resistant to oxyiminocephalosporins without extended spectrum b-lactamase production. FEMS Microbiol Lett 1999; 173: 459-65.
22. Caroff N, Espaze E, Gautreau D et al. Analysis of the effects of 242 and 232 ampC promoter mutations in clinical isolates of Escherichia coli hyperproducing ampC. J Antimicrob Chemother 2000; 45: 783-8.
23. Jacoby GA. Mechanisms of resistance to quinolones. Clin Infect Dis 2005; 41 Suppl 2: S120-6.
24. Cattoir V, Nordmann P. Plasmid-mediated quinolone resistance in gram-negative bacterial species: an update. Curr Med Chem 2009; 16: 1028-46.
25. Zankari E, Hasman H, Cosentino S et al. Identification of acquired antimicrobial resistance genes. J Antimicrob Chemother 2012; 67: 2640-4.
26. Lunter G, Goodson M. Stampy: a statistical algorithm for sensitive and fast mapping of Illumina sequence reads. Genome Res 2011; 21: 936-9.
27. Zerbino DR, Birney E. Velvet: algorithms for de novo short read assembly using de Bruijn graphs. Genome Res 2008; 18: 821-9.
28. Gladman S, Seemann T. VelvetOptimiser. http://bioinformatics.net.au/ software.velvetoptimiser.shtml (27 December 2012, date last accessed).
29. Gouy M, Guindon S, Gascuel O. SeaView version 4: A multi-platform graphical user interface for sequence alignment and phylogenetic tree-building. Mol Biol Evol 2010; 27: 221-4.
30. Sutcliffe JG. Nucleotide sequence of the ampicillin resistance gene of Escherichia coli plasmid pBR322. Proc Natl Acad Sci USA 1978; 75: 3737-41.
31. Yuan J, Xu X, Guo Q et al. Prevalence of the oqxAB gene complex in Klebsiella pneumoniae and Escherichia coli clinical isolates. J Antimicrob Chemother 2012; 67: 1655-9.
32. Card R, Zhang J, Das P et al. Evaluation of an expanded microarray for detecting antibiotic resistance genes in a broad range of Gram-negative bacterial pathogens. Antimicrob Agents Chemother 2012; 57: 458-65.
33. Davis MA, Baker KN, Orfe LH et al. Discovery of a gene conferring multiple-aminoglycoside resistance in Escherichia coli. Antimicrob Agents Chemother 2010; 54: 2666-9.
34. Bond A, Plumb H, Turner P. Susceptibility testing of Escherichia coli isolates from urines: are we at risk of reporting false antibiotic resistance to co-amoxiclav? J Antimicrob Chemother 2012; 67: 1557-8.
35. Cantón R, Loza E, Del Carmen Conejo M et al. MENSURA Collaborative Group. Quality control for b-lactam susceptibility testing with a well-defined collection of Enterobacteriaceae and Pseudomonas aeruginosa strains in Spain. J Clin Microbiol 2003; 41: 1912-8.
36. Wang P, Hu F, Xiong Z et al. Susceptibility of extendedspectrum-b-lactamase-producing Enterobacteriaceae according to the new CLSI breakpoints. J Clin Microbiol 2011; 49: 3127-31.
37. Williamson DA, Roberts SA, Smith M et al. High rates of susceptibility to ceftazidime among globally prevalent CTX-M-producing Escherichia coli: potential clinical implications of the revised CLSI interpretive criteria. Eur J Clin Microbiol Infect Dis 2012; 31: 821-4.
38. Livermore DM, Andrews JM, Hawkey PM et al. Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly? J Antimicrob Chemother 2012; 67: 1569-77.
39. Novais A, Rodrigues C, Branquinho R et al. Spread of an OmpK36-modified ST15 Klebsiella pneumoniae variant during an outbreak involving multiple carbapenem-resistant Enterobacteriaceae species and clones. Eur J Clin Microbiol Infect Dis 2012; 31: 3057-63.
40. Güell M, Yus E, Lluch-Senar M et al. Bacterial transcriptomics: what is beyond the RNA horiz-ome? Nat Rev Microbiol 2011; 9: 658-69.